PMH42 Treatment Continuation and Treatment Characteristics of 3 Long Acting Antipsychotic Medications (Paliperidone Palmitate, Risperidone Microspheres and Haloperidol Decanoate) in Belgium  by Sermon, J. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A461
caring. It provided direct payments and aid to allow carers to take a break from caring 
(with or without the person cared for). Here we investigate the effects of the scheme 
on carers’ HRQL. Methods: In order to conduct the evaluation, a quality of life survey 
was conducted. Carers were asked to complete questionnaires at Week 0 and Week 
12. One of the questionnaires selected for inclusion in both surveys was the EQ-5D 
(5 level). Results: Of the 155 patients completing the Week 0 survey, 97 completed 
at least some of the Week 12 survey. There was some evidence to suggest a small 
improvement in HRQL via the EQ-5D-5L (0.62 to 0.66, n= 86). Both pre- and post-inter-
vention the estimated mean utility of the cohort was significantly lower than 0.81; 
the value that would be predicted in the general population given the age and gender 
characteristics of the cohort. ConClusions: Informal carers have significantly lower 
HRQL than age-matched controls. While it is not possible to draw firm conclusions 
around the benefit derived from the intervention, due to the lack of control arm, the 
evaluation of a carer breaks service indicates a potentially modest benefit.
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objeCtives: To understand social and work impacts of caring for children/
adolescents with attention-deficit/hyperactivity disorder (ADHD) in Sweden 
relative to a combined cohort of other Nordic countries (Denmark, Finland and 
Norway). Methods: Carers in Sweden and other Nordic countries completed the 
Caregiver Perspective of Pediatric ADHD (CAPPA) online survey capturing carer 
impacts, including work, social activities and family relationships, due to their 
child’s ADHD. Impacts were explored when the child was “on” and “off” medica-
tion (e. g. days medication not taken). Comparisons of “on” and “off” medication 
were examined using the Wilcoxon Signed-Rank test. No statistical comparisons of 
impacts were made between countries. Results: 219 Swedish and 249 other Nordic 
carers of ADHD children aged 6–17 years completed the survey. 37% of Swedish 
carers reported employment changes (e. g. resigned, changed shift, reduced hours) 
due to their child’s ADHD; 52% of these changes occurred when the child was “on” 
medication. In the past 4 weeks, 60% of Swedish carers reported missing work and 
45% reported being late for work. After excluding outliers (n= 15), mean number 
of hours missed was 4.32 (n= 91, SD 2.53) and mean number of times late was 2.91 
(n= 69, SD 1.35). Swedish carers reported fewer “moderate” to “tremendous” impacts 
on social life when their child was “on” versus “off” medication (partner relationship 
strain: 37% vs 67%; relationship strain with other children: 29% vs 57%; social activity 
interference: 40% vs 59%). Relative to other Nordic countries, more Swedish carers 
reported being late for work (36% vs 45%) and more “moderate” to “tremendous” 
interference with social activities while the child was medicated (29% vs 40%). All 
other impacts described were similar between the two cohorts. ConClusions: 
While medication helped, it did not completely alleviate child ADHD-related impacts 
on work and social activities among carers from Sweden and other Nordic countries.
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objeCtives: Clinically relevant anxiety is a highly prevalent co-morbidity in chronic 
obstructive pulmonary disease (COPD), affecting up to 74% of patients. However, 
despite its prevalence, co-morbid anxiety remains under-recognised and under-
managed. Furthermore, its identification and measurement can be confounded by 
the overlap of somatic symptoms between anxiety and COPD. This study sought to 
evaluate the ability of existing patient-reported outcome (PRO) measures to assess 
anxiety in COPD through conceptual mapping, with particular attention on the 
coverage of non-somatic anxiety symptoms. Methods: To determine conceptual 
comprehensiveness, the content of 12 extant anxiety PROs was mapped to a concep-
tual model of anxiety in COPD, developed through a qualitative literature review and 
in-depth qualitative interviews (n= 15) of COPD patients with anxious symptomol-
ogy. Results: The conceptual model contained 29 concepts within five domains 
(somatic [15 concepts]; psychic tension [5 concepts]; apprehension [5 concepts]; 
panic [3 concepts]; behavioural [1 concept]). The most comprehensive conceptual 
coverage was found in the Mind Over Mood Anxiety Inventory which assesses 18/29 
(62%) concepts across all five domains. Concept mapping revealed the majority of 
PROs are biased toward assessing somatic symptoms of anxiety, with no measure 
providing comprehensive assessment of non-somatic concepts. Indeed, the two 
most widely used anxiety PROs in COPD research and clinical practice (Beck Anxiety 
Inventory [BAI] and Hospital Anxiety and Depression Scale) provide sub-optimal cov-
erage of anxiety concepts. In particular, the BAI is heavily weighted toward assessing 
somatic concepts, with little focus on psychic, apprehensive, panic and behavioural 
concepts of anxiety. ConClusions: In light of the sub-optimal content validity of 
extant instruments, including those commonly used in research and practice, there 
is a need for a comprehensive COPD-specific anxiety PRO. Such an instrument can 
be utilised in clinical trials for evaluating new products and enhance the accuracy 
of anxiety screening and measurement in clinical practice.
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objeCtives: The Anxiety Inventory for Respiratory disease (AIR) is a novel, non-
somatic patient-reported outcome (PRO) measure of anxiety among patients with 
chronic obstructive pulmonary disease (COPD). Traditional psychometric meth-
medicine. The study provides a baseline data for further studies on patients’ adher-
ence to psychotropic medications.
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objeCtives: Treatment continuation of 3 long acting, injectable, antipsychotic 
drugs: paliperidone palmitate, risperidone microspheres and haloperidol decanoate, 
was evaluated in the Belgian outpatient setting using panel data from public phar-
macies. Drug dosage, age distribution and frequency of co-prescribed antipsychotic 
medications were investigated. Methods: IMS LifelinkTM Treatment Dynamics 
database was used, applying appropriate selection criteria. Three patient cohorts 
that started paliperidone palmitate, risperidone microspheres or haloperidol 
decanoate treatment respectively, between 1 December 2011 and 31 August 2012, 
were analyzed. All cohorts included at least 13 months of follow up. Treatment 
continuation was investigated. Results: After 90 and 180 days, more patients 
continued treatment with paliperidone palmitate (60,71% and 42,41% respectively) 
than with risperidone microspheres (39, 07% and 26, 49%) or haloperidol decanoate 
(34,23% and 17,57%). Within 3 months after discontinuation, more patients restarted 
their treatment when using paliperidone palmitate (41%) compared to risperidone 
microspheres (27%) or haloperidol decanoate (17%). For all therapies, dosing was 
comparable between treatment initiation and discontinuation. Patients treated 
with paliperidone palmitate were generally younger (patients ≤ 32 years: paliperi-
done palmitate, 26%; risperidone microspheres, 17%; or haloperidol decanoate, 5%). 
Over 1 year, on average 62% of patients used paliperidone palmitate or risperidone 
microspheres in monotherapy. In contrast, haloperidol decanoate in monotherapy 
declined over time (from 49% to 28% in 1 year). Medication against extrapyramidal 
symptoms was on average more used with haloperidol decanoate (37%) than with 
paliperidone palmitate (16%) or risperidone microspheres (18%). ConClusions: 
Results of the database research indicate that more patients treated with paliperi-
done palmitate continued their therapy, restarted therapy and were of younger 
age than patients receiving risperidone microspheres or haloperidol decanoate. 
Monotherapy was more frequently observed with paliperidone palmitate and risp-
eridone microspheres while co-medication against extrapyramidal symptoms was 
less frequently used compared to with haloperidol decanoate.
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objeCtives: Research indicates schizophrenia is a cause of burden for patients and 
caregivers. This study examined health-related quality of life (HRQoL) and comor-
bidities experienced by schizophrenia caregivers compared to non-caregivers and 
caregivers of other conditions. Methods: Data were obtained from the 2010-2011 
and 2013 5E. U. (UK, Germany, France, Italy, Spain) National Health and Wellness 
Survey, an online questionnaire that’s representative of the total adult (18+ years) 
population. Respondents provided information on HRQoL (SF-36v2: mental and 
physical component summary (MCS, PCS) and SF-6D (health utility) scores), and 
comorbidities (sleep-difficulties, insomnia, pain, headaches, heartburn, anxiety, 
depression) experienced in the past 12 months. Schizophrenia caregivers (n= 398) 
were matched to non-caregivers (n= 158,989) and other caregivers (n= 14,341) on 
baseline characteristics (age, gender, income, etc.) via propensity scores (1:2). Chi-
square tests and ANOVAs were used to determine significant differences across the 
groups. Results: The average age of schizophrenia caregivers was 45.3 (SD= 15.8 
years), 59.6% were female, and 14.8% reported an income of € 50,000/£40,000+. After 
matching, schizophrenia caregivers reported significantly lower MCS (40.3 vs. 45.9), 
PCS (46.8 vs. 49.0) and health utilities (0.64 vs. 0.71), compared to non-caregivers (all 
p< 0.001). Schizophrenia caregivers reported experiencing significantly more sleep 
difficulties (42.7% vs. 28.5%), insomnia (32.4% vs. 18.5%), pain (39.7% vs. 30.4%), 
headaches (48.0% vs. 42.0%), heartburn (31.7% vs. 22.9%), anxiety (37.9% vs. 23.6%), 
and depression (29.4% vs. 19.4%) than non-caregivers. Comparing schizophrenia 
caregivers and other caregivers, schizophrenia caregivers reported lower MCS (40.3 
vs. 42.7, p< 0.001), and health utilities (0.64 vs. 0.67, p< 0.001). Schizophrenia caregiv-
ers reported significantly more sleep difficulties (42.7% vs. 36.8%), insomnia (32.4% 
vs. 26.0%), pain (39.7% vs. 31.5%), and anxiety (37.9% vs. 29.8%) than other caregiv-
ers. ConClusions: Schizophrenia caregivers reported worse HRQoL and more 
comorbidities than non-caregivers and caregivers of other conditions. Providing 
caregivers with support services to better manage patients effectively may improve 
caregiver’s health status.
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objeCtives: Informal carers are widely acknowledged to be an important part of 
health care provision, as well as a source of substantial cost savings to the health 
care system. It has been observed, however, that carers have worse health-related 
quality of life (HRQL) than the general population. As a result of this, the wellbeing 
of carers has been set as a government priority. In Bristol, UK, the National Health 
Service and council jointly funded a 12-week scheme to facilitate breaks from 
